KCT0008486招募中Unknown
Efficacy, Safety and Economic Evaluation of Gamidaeganghwal-tang for Degenerative Knee Osteoarthritis : A multicenter, randomized, double-blind, parallel clinical trial
Kyung Hee University Oriental Medicine Hospital at Gangdong0 个研究点目标入组 240 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40(Year) 至 70(Year)（—）
- 性别
- All
入选标准
- •1. Adults aged from 40 to 70
- •2. Patients suffering knee pain from knee osteoarthritis for more than 3 months.
- •3. Patients diagnosed with knee osteoarthritis according to ACR criteria and at the same time, whose target lesion is Kellgren-Lawrence grade ?~? in simple X-ray.
- •4. Patients with a total score of 30 or higher on KOWAC which is done at the screening visit.
- •5. Patients who can agree to discontinue any existing treatment and can cooperate.
- •6. Patients voluntarily agreed to participate in the study
- •7. Patients with unilateral osteoarthritis or bilateral osteoarthritis whose target lesion can be designated to one side according to the following standard: If both knees meet the selection/exclusion criteria, target lesions are designated according to the criteria below.
- •? Designate the one with the higher Kellgren-Lawrence grade as the target lesion.
- •? If the Kellgren-Lawrence grade is the same, the one with the higher pain felt by the subject during the screening interview is designated as the target lesion.
- •? If all criteria of ?~? are the same, designate the right knee as the target lesion.
排除标准
- •1. Patients with a history of knee joint trauma within 6 months of screening
- •2. Patients with a history of knee joint surgery or a plan for surgery during the clinical study period
- •3. Patients with a history of the following treatment:
- •- intra-articular injection treatments such as intra-articualr corticosteroid within 6 months of screening
- •- injections such as hyalurnoic acid injcetion within 6 months of screening
- •4. Patients who are suspected to have following diseases in physical examination and diagnostic examination
- •: rheumatoid arthritis, autoimmune disease, septic arthritis, inflammatory joint disease, gout, recurrent pseudogout, Paget's disease, joint fractures, histioplegia, acromegaly, hemochromatosis, Wilson's disease, primary osteochondrosis, genetic disorders (e.g. hyperkinesia), collagen gene abnormality etc.
- •5. Patients with musculoskeletal disorders that may affect this study as judged by the researcher (e.g. hip or spine problems)
- •6. Patients receiving treatment for mental disorders such as depression and schizophrenia
- •7. Patients with liver disease (AST or ALT > 2 times the normal range)
- •8. Patients with renal disease (serum creatinine > 2.0 ?/?)
- •9. Patients with other diseases that may interfere with treatment, such as serious gastrointestinal or cardiovascular diseases, uncontrolled hypertension or diabetes, serious kidney or liver diseases, or hemorrhagic diseases
- •10. Patients with a history of hypersensitivity or allergy to the components of investigational product.
- •11. Patients with galactose intolerance or lactase deficiency
- •12. Patients with a history of hypersensitivity to piroxicam, aspirin asthma or patients who develop urticaria, rhinitis or angioedema to aspirin or other non-steroidal anti-inflammatory drugs.
- •13. Patients who are taking herbal medicines or health functional foods that overlaps with investigational products.
- •14. Pregnant or lactating women
- •15. Patients whom the researcher judged not suitable for herbal medicine treatment
- •16. Patients who have participated in another clinical trial within either 4 weeks of the start of the clinical trial or 5 times of the half-life of an investigational product or are currently participating in another clinical trial
- •17. Patients with difficulty in stopping taking anti-inflammatory drugs
- •18. Participants deemed by the researchers to be unqualified to participate in the clinical trial.
研究者
相似试验
进行中（未招募）
1 期
GAP Study: Gabapentin in post surgery paiPost surgery pain managementMedDRA version: 20.0 Level: LLT Classification code 10036237 Term: Post operative analgesia System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0 Level: PT Classification code 10056350 Term: Pain management System Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0 Level: LLT Classification code 10036286 Term: Post-operative pain System Organ Class: 100000004863EUCTR2017-002078-38-GBniversity Hospitals Bristol NHS Foundation Trust1,500
招募中
Unknown
Effects, safety, and study feasibility of Gamisoyo-san on dysmenorrhea patients with premenstrual syndromeKCT0009472Daejeon Korean Medicine Hospital of Daejeon University30
招募中
4 期
A real-world study of the safety and efficacy of Ganmaoling granules (999) in the treatment of the common coldcommon coldITMCTR2000002998China-Japan Friendship Hospital
招募中
不适用
Efficacy, safety and economic evaluation of Dangguijagyak-san for primary dysmenorrhea; a randomized, double-blind, parallel-group, multi-center, investigator-initiated clinical trialDiseases of The genitoruinary systemKCT0003005Kyung Hee University Oriental Medicine Hospital at Gangdong240
进行中（未招募）
1 期
Evaluation of the efficacy and safety of sugammadex (Bridion) in children with renal failure. - sugammadex in children with renal failureSugammadex is a selective relaxant binding agent, which is administered in case of a rocuronium-induced neuromuscular block, during general anaesthesia. The aim of the trial is to investigate the use, efficacy and safety of sugammadex in children (2-17 years) with moderate to severe renal failure (creatinine clearance < 30 ml/min), compared to children with normal renal function.MedDRA version: 9.1Level: HLTClassification code 10038443Term: Renal failure and impairmentMedDRA version: 9.1Level: LLTClassification code 10009119Term: Chronic renal failureMedDRA version: 9.1Level: LLTClassification code 10014647Term: End stage renal failureEUCTR2008-008246-20-NLRadboud University Nijmegen Medical Center, Department of Anaesthesiology, Pain and Palliative Medic20